| HOME >> BIOLOGY >> TECHNOLOGY |
CAMBRIDGE, England, November 6, 2012 /PRNewswire/ --
Cambridge biotech company Arecor has been awarded £785,000 from the government-backed Biomedical Catalyst Fund to accelerate the development of high concentration antibodies to allow more convenient administration of our future therapeutic medicines and reduce healthcare costs. Arecor has recently demonstrated Proof of Concept in developing stable aqueous formulations of a number of high concentration monoclonal antibodies.
The award was announced by Technology Strategy Board on Sunday, 4th November 2012 and is one of 32 projects awarded funding totalling £39 million. These are the first substantial awards made from the £180 million Biomedical Catalyst programme managed by the Technology Strategy Board and the Medical Research Council.
Arecor is a pioneer in the stabilisation of biologic molecules, a key challenge in the development of many therapeutic proteins, vaccines and diagnostics. Many proteins, peptides or vaccines are too unstable in liquid form to develop ready-to-use drugs or are unstable at high concentrations. Arecor has developed a set of unique technologies to address these problems with the potential to revolutionise the development, use and distribution of the next generation of therapeutic medicines.
Tom Saylor, CEO of Arecor, said the award will go towards a £1.3 million project to drive forward their innovative research:
"Arecor is delighted to have been awarded an inaugural Biomedical Catalysts funding from the Technology Strategy Board which justifies our position as a leader in the field of stable aqueous formulation and confidence in our platform for stabilising anitbody therapies at high concentration, as well as recognising the expertise of our dedicated scientists."
David Willetts, Minister for Universities and Science, said:
"Britain is in a global race today and this £39 million investment w
'/>"/>
| SOURCE Arecor Copyright©2012 PR Newswire. All rights reserved |